Abstracts tagged "Bone density"

Abstract Number: 208 • 2014 ACR/ARHP Annual Meeting
Correlates of Knee Bone Marrow Lesions in Younger Adults
Benny Samuel Eathakkattu Antony¹, Graeme Jones², Alison Venn³, Lyn March⁴, Flavia Cicutinni⁵, Andrew Halliday⁶, Leigh Blizzard⁷, Marita Cross⁸, Terry Dwyer⁹ and Changhai Ding², ¹Musculoskeletal, Menzies Research Institute Tasmania, University of Tasmania, Hobart, Australia, ²Musculoskeletal Unit, Menzies Research Institute Tasmania, University of Tasmania, Hobart,7000, Australia, ³Epidemiology, Menzies Research Institute Tasmania, University of Tasmania, Hobart, Tasmania, Australia, ⁴Rheumatology, Institute of Bone and Joint Research, Kolling Institute, University of Sydney, Sydney, Australia, ⁵Department of Epidemiology and Preventive Medicine, Monash University, Monash University, Melbourne, Australia, Melbourne, Australia, ⁶Radiology, Royal Hobart Hospital, Australia, Hobart, Australia, ⁷Statistics, Menzies Research Institute Tasmania, University of Tasmania, Hobart, Tasmania, Australia, ⁸University of Sydney Institute of Bone and Joint Research, Royal North Shore Hospital, Sydney, Australia, ⁹Director, Murdoch Children's Research Institute, Melbourne, Australia
Background/Purpose: Bone marrow lesions (BMLs) of the knee joint are a key player in osteoarthritis of the knee. However, little is known of their determinants,…
Abstract Number: 2287 • 2014 ACR/ARHP Annual Meeting
Cartilage Thickness and Bone Health in Children with Juvenile Idiopathic Arthritis
Marinka Twilt¹, Dan Pradsgaard², Anne Helene Spannow², Arne Horlyck³, Carsten Heuck² and Troels Herlin⁴, ¹Paediatrics, Aarhus University Hospital, Aarhus, Denmark, ²paediatrics, Aarhus University Hospital, Aarhus, Denmark, ³radiology, Aarhus University Hospital, Aarhus, Denmark, ⁴Pediatric Rheumatology Clinic, Department of Pediatrics, Aarhus University Hospital, Aarhus, Denmark
Background/Purpose Although treatment options have increased and morbidity has decreased in the last decade Juvenile Idiopathic Arthritis (JIA) may still result in disability. Increasingly ultrasonography…
Abstract Number: 62 • 2014 ACR/ARHP Annual Meeting
Severe Spine Osteoarthritis in Older Men Is Associated with the Risk of Incident Fragility Fracture
Roland Chapurlat¹, Charline Estublier² and Pawel Szulc³, ¹Pavillon F Rheumatology, Hopital Edouard Herriot, Lyon, France, ²Rheumatology, Hôpital Edouard Herriot, Pavillon F, Lyon, France, ³Epidemiology of Osteoporosis, INSERM UMR 1033, Lyon, France
Background/Purpose: Data on the association of osteoarthritis (OA) with bone fragility are limited. In particular, data on the fracture risk in older men with spine…
Abstract Number: 2255 • 2014 ACR/ARHP Annual Meeting
Vertebral Cortical Bone Mass and Structure Significantly Improved with Romosozumab Compared with Teriparatide: HR-QCT Analyses of Postmenopausal Women with Low BMD from a Phase 2 Study
T Damm¹, C Libanati², J Peña¹, G Campbell¹, R Barkmann¹, DA Hanley³, S Goemaere⁴, MA Bolognese⁵, C Recknor⁶, C Mautalen⁷, YC Yang² and CC Glüer¹, ¹Christian-Albrechts-Universität zu Kiel, Kiel, Germany, ²Amgen Inc., Thousand Oaks, CA, ³University of Calgary, Calgary, AB, Canada, ⁴Ghent University Hospital, Ghent, Belgium, ⁵Bethesda Health Research Center, Bethesda, MD, ⁶United Osteoporosis Centers, Gainesville, GA, ⁷Centro de Osteopatias Medicas, Buenos Aires, Argentina
Background/Purpose : Understanding the effect of therapies in the vertebral compartments is relevant to bone biology and clinical practice. We developed an improved technique using…
Abstract Number: 2149 • 2014 ACR/ARHP Annual Meeting
Relationship Between the Magnitude of Bone Formation in the Anterior Vertebral Corners, As Assessed through 18F-Fluoride Uptake, and Lumbar Spine Bone Mineral Density in Patients with Ankylosing Spondylitis
Seung-Geun Lee¹, Eun-Kyoung Park¹, Geun-Tae Kim², Sang-Yeob Lee³ and Joung-Wokk Lee⁴, ¹Divsion of Rheumatology, Department of Internal Medicine, Pusan National University School of Medicine, Pusan National University Hospital, Busan, South Korea, ²Division of Rheumatology, Department of Internal Medicine, Kosin University College of Medicine, Busan, South Korea, ³Division of Rheumatology, Department of Internal Medicine, Dong-A University College of Medicine, Busan, South Korea, ⁴Divsion of Rheumatology, Department of Internal Medicine, Busan St. Marys center, Busan, South Korea
Background/Purpose: 18F-fluoride uptake represents active osteoblastic bone synthesis. We investigated the relationship between the magnitude of bone formation in anterior vertebral corners, as assessed through…
Abstract Number: 2013 • 2014 ACR/ARHP Annual Meeting
Quality Appraisal of Educational Websites on Osteoporosis and Bone Health
Maria A. Lopez-Olivo¹, Noha Abdel-Wahab^2,3, Abhinav Dodeja⁴, Gregory Pratt⁵ and Maria E. Suarez-Almazor², ¹Department of General Internal Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX, ²The Department of General Internal Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX, ³Rheumatology & Rehabilitation Department, Assiut University Hospital, Assiut, Egypt, ⁴The University of Texas Health Science Center, School of Public Health, Houston, TX, ⁵Research Medical Library, The University of Texas, MD Anderson Cancer Center, Houston, TX
Background/Purpose: Osteoporosis, like many other chronic diseases, can have better outcomes when informed patients get involved in self-management, resulting in better ourtcomes. Bone health education…
Abstract Number: 1818 • 2014 ACR/ARHP Annual Meeting
Subchondral Bone Mineral Density Improves Prediction of Knee Osteoarthritis Progression Compared with Clinical Factors Alone: Data from the Osteoarthritis Initiative
Michael P. Lavalley¹, Grace H. Lo², Lori Lyn Price³, Jeffrey Driban⁴, Charles Eaton⁵ and Timothy E. McAlindon⁶, ¹Biostatistics, Boston University, Boston, MA, ²VA HSR&D Center for Innovations in Quality, Effectiveness and Safety; Medical Care Line and Research Care Line; Department of Medicine, Michael E. DeBakey VA Medical Center, Baylor College of Medicine, Houston, TX, ³Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, ⁴Tufts Medical Center, Boston, MA, ⁵Center for Primary Care and Prevention, Memorial Hospital of Rhode Island, Providence, RI, ⁶Division of Rheumatology, Tufts Medical Center, Boston, MA
Background/Purpose A prediction rule for knee osteoarthritis (OA) progression would have great clinical utility in identifying at-risk patients for intervention. Rules using clinically available measurements…
Abstract Number: 1795 • 2014 ACR/ARHP Annual Meeting
Denosumab Restores Cortical Bone Loss at the Distal Radius Associated with Aging and Reduces Wrist Fracture Risk: Analyses from the Cross-over Group in the Extension of the Denosumab Pivotal Fracture Trial
JP Bilezikian¹, CL Benhamou², CJF Lin³, JP Brown⁴, NS Daizadeh³, PR Ebeling⁵, A Fahrleitner-Pammer⁶, E Franek⁷, N Gilchrist⁸, PD Miller⁹, JA Simon¹⁰, I Valter¹¹, CAF Zerbini¹² and C Libanati³, ¹College of Physicians and Surgeons, Columbia University, New York, NY, ²CHR d'Orléans, Orléans, France, ³Amgen Inc., Thousand Oaks, CA, ⁴CHU de Québec Research Centre and Laval University, Quebec City, QC, Canada, ⁵Monash University, Clayton, Australia, ⁶Medical University, Graz, Austria, ⁷Medical Research Center, Polish Academy of Sciences, Warsaw, Poland, ⁸The Princess Margaret Hospital, Christchurch, New Zealand, ⁹Colorado Center for Bone Research, Lakewood, CO, ¹⁰George Washington University, Washington, DC, ¹¹Center for Clinical and Basic Research, Tallinn, Estonia, ¹²Centro Paulista de Investigação Clinica, São Paulo, Brazil
Background/Purpose: Cortical bone loss is a major determinant of increased fracture risk. Denosumab (DMAb) has been shown to increase BMD at sites of cortical bone,…
Abstract Number: 1490 • 2014 ACR/ARHP Annual Meeting
Can Tumor Necrosis Factor Inhibitors Protect Rheumatoid Arthritis Patients from Osteoporosis? Impact of Tumor Necrosis Factor Inhibitors on Bone Mineral Density and Bone Remodeling Markers
Anaïz Nutz¹, Yohan Duny², Thomas Barnetche³, Jacques Morel⁴, Bernard Combe⁵ and Claire Daien⁶, ¹Rheumatology, Hopital Lapeyronie, Montpellier, France, ²INSERM, Montpellier, France, ³Department of rheumatology, Bordeau, France, ⁴Department of Rheumatology, Hôpital Lapeyronie, Montpellier, France, ⁵Immuno-Rhumatologie, Hôpital Lapeyronie, Montpellier, France, ⁶Hopital Lapeyronie, Montpellier, France
Background/Purpose Rheumatoid Arthritis (RA) is a chronic inflammatory disease characterized by joint and bone destruction. Loss of bone in RA is not only localized in…
Abstract Number: 1301 • 2014 ACR/ARHP Annual Meeting
Trabecular Bone Impairment Assessed By HR-pQCT in Juvenile-Onset Systemic Lupus Erythematous with Vertebral Fractures
Juliane Paupitz, Glauce Lima, Valéria Caparbo, Henrique Fuller, Eloisa Bonfa and Rosa M R Pereira, Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
Background/Purpose The three-dimensional evaluation of bone by HR-pQCT has the advantage to provide assessment to not only bone density, but also to a noninvasive evaluation…
Abstract Number: 1246 • 2014 ACR/ARHP Annual Meeting
Assessment of Protective Factors of Bone Mineral Density in a New Orleans Sarcoidosis Population
McCall Walker¹, Harmanjot K. Grewal², Adam Janot³, Mary Yu⁴, Sophia Cenac⁵, Matthew R. Lammi^6,7 and Lesley Ann Saketkoo⁸, ¹LSUHSC School of Medicine, New Orleans, LA, ²Rheumatology, Lousiana State University Health Sciences Center, New Orleans, LA, ³Department of Ophthalmology, Virginia Commonwealth University –Medical College of Virginia, Charlottesville, VA, ⁴Internal Medicine, Louisiana State University Health Sciences Center, New Orleans, LA, ⁵Scleroderma and Sarcoidosis Patient Care and Research Center, Louisiana State University Health Science Center, New Orleans, LA, ⁶Louisiana State University Health Sciences Center, Pulmonary and Critical Medicine, New Orleans, LA, ⁷Section of Pulmonary and Critical Care Medicine, LSU Scleroderma and Sarcoidosis Patient Care and Research Center, New Orleans, LA, ⁸Scleroderma and Sarcoidosis Patient Care and Research Center, Rheumatology and Pulmonary Medicine, Louisiana State University Health Sciences Center, New Orleans, LA
Background/Purpose: Sarcoidosis often involves pathological dysregulation of dependent factors of bone metabolism, e.g. calcitriol /calcium, and administration of high dose glucocorticoids (GCs) leading to low…
Abstract Number: 238 • 2014 ACR/ARHP Annual Meeting
RANKL and OPG Gene Polymorphisms: Association with Vertebral Fractures and Bone Mineral Density in Premenopausal Systemic Lupus Erythematosus
Alessandra C. Bonfa¹, Luciana P.C. Seguro², Valéria Caparbo³, Eloisa Bonfa³ and Rosa M R Pereira³, ¹Rheumatology, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ²Division of Rheumatology, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ³Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
Background/Purpose To evaluate single nucleotide polymorphisms (SNPs) of the receptor activator of NF-κB ligand (RANKL), RANK and osteoprotegerin (OPG) genes in premenopausal systemic lupus erythematosus…
Abstract Number: 863 • 2013 ACR/ARHP Annual Meeting
Romosozumab Administration Is Associated With Significant Improvements In Lumbar Spine and Hip Volumetric Bone Mineral Density and Content Compared With Teriparatide
H K Genant¹, S Boonen², M A Bolognese³, C Mautalen⁴, J P Brown⁵, C Recknor⁶, S Goemaere⁷, K Engelke⁸, Y-C Yang⁹, M Austin⁹, A Grauer⁹ and C Libanati⁹, ¹UCSF & Synarc Inc., San Francisco, CA, ²Leuven University Division of Geriatric Medicine, Leuven, Belgium, ³The Bethesda Health Research Center, Bethesda, MD, ⁴Centro de Osteopatias Medicas, Buenos Aires, Argentina, ⁵CHU de Québec Research Centre and Laval University, Québec, QC, Canada, ⁶United Osteoporosis Centers, Gainesville, GA, ⁷Ghent University Hospital, Ghent, Belgium, ⁸Synarc Germany, Hamburg, Germany, ⁹Amgen Inc., Thousand Oaks, CA
Background/Purpose: Sclerostin is an osteocyte-derived inhibitor of osteoblast activity. Romosozumab, a monoclonal antibody to sclerostin stimulates bone formation and decreases bone resorption. In a phase…
Abstract Number: 864 • 2013 ACR/ARHP Annual Meeting
Further Reduction In Nonvertebral Fracture Rate Is Observed Following 3 Years Of Denosumab Treatment: Results With Up To 7 Years In The Freedom Extension
Jonathan D. Adachi¹, Serge Ferrari², Carol Zapalowski³, Paul D. Miller⁴, Jean-Yves Reginster⁵, Ove Törring⁶, Nadia Daizadeh³, Andrea Wang³, Cynthia O'Malley⁷, Rachel B. Wagman³ and E. Michael Lewiecki⁸, ¹McMaster University, Hamilton, ON, Canada, ²Geneva University Hospital, Geneva, Switzerland, ³Amgen Inc., Thousand Oaks, CA, ⁴Colorado Center for Bone Research, Lakewood, CO, ⁵University of Liège, Liège, Belgium, ⁶Karolinska Institutet, Södersjukhuset, Stockholm, Sweden, ⁷Center for Observational Research, Amgen, Inc., Thousand Oaks, CA, ⁸New Mexico Clinical Research & Osteoporosis Center, Albuquerque, NM
Further Reduction in Nonvertebral Fracture Rate Is Observed Following 3 Years of Denosumab Treatment: Results With up to 7 Years in the FREEDOM ExtensionBackground/Purpose: Some…
Abstract Number: 865 • 2013 ACR/ARHP Annual Meeting
Vertebral Fractures In The 3 Year Period Following Steroid Initiation Among Children With Chronic Illnesses
Johannes Roth¹, Jinhui Ma¹, David A. Cabral², Peter B. Dent³, Janet E. Ellsworth⁴, Adam M. Huber⁵, Kristin M. Houghton², Roman Jurencak¹, Bianca A. Lang⁵, Maggie Larche³, Claire MA Leblanc⁶, Brian Lentle², MaryAnn Matzinger¹, Paivi M. Miettunen⁷, Kiem Oen⁸, Claire Saint-cyr⁹, Rosie Scuccimarri¹⁰, Nazih Shenouda¹, Leanne M. Ward¹ and The Canadian STOPP Consortium¹¹, ¹University of Ottawa, Ottawa, ON, Canada, ²University of British Columbia, Vancouver, BC, Canada, ³McMaster University, Hamilton, ON, Canada, ⁴University of Alberta, Edmonton, AB, Canada, ⁵Dalhousie University, Halifax, NS, Canada, ⁶McGill University, Montréal, QC, Canada, ⁷University of Calgary, Calgary, AB, Canada, ⁸University of Manitoba, Winnipeg, MB, Canada, ⁹Université de Montréal, Montreal, QC, Canada, ¹⁰McGill University, Montreal, QC, Canada, ¹¹National Pediatric Bone Health Working Group, Ottawa, ON, Canada
Background/Purpose: : To describe the pattern and frequency of incident vertebral fractures (VF) in glucocorticoid (GC)-treated children and to determine the clinical factors at baseline…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].